diphtheria + tetanus + pertussis + Vi-rEPA

This drug entry refers to the co-administration regimen of the routine diphtheria, tetanus, and pertussis (DTP) vaccine with the investigational Vi-rEPA typhoid conjugate vaccine, developed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Vi-rEPA is a conjugate vaccine consisting of the Vi capsular polysaccharide of Salmonella enterica serovar Typhi covalently bound to a recombinant exoprotein A of Pseudomonas aeruginosa (rEPA), which serves as a carrier protein to enhance immunogenicity in infants. The combination was evaluated in clinical trials in Vietnam to assess the safety, immunogenicity, and compatibility of adding the typhoid conjugate vaccine to the standard Expanded Program on Immunization (EPI) schedule at 2, 4, 6, and 12 months of age. The Vi-rEPA component has demonstrated high efficacy (89-91.5%) in preventing blood culture-confirmed typhoid fever in children.

Other names

diphtheria + tetanus + pertussis-Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-Typhoid FeverVi-rEPA conjugate vaccineTyphoid Vi-rEPA vaccineVi-rEPA + DTP